US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
JPH0742304B2
(ja)
|
1986-12-05 |
1995-05-10 |
財団法人微生物化学研究会 |
新規なアンスラサイクリン誘導体およびその製造法
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
DE3712350A1
(de)
|
1987-04-11 |
1988-10-20 |
Behringwerke Ag |
Semisynthetische rhodomycine, verfahren zu ihrer herstellung und ihre verwendung als zytostatika
|
EP0335369A3
(en)
|
1988-03-29 |
1990-03-28 |
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai |
New anthracycline derivatives and processes for the preparation of the same
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
CA2062795A1
(en)
|
1989-06-29 |
1990-12-30 |
Michael W. Fanger |
Bispecific reagents for aids therapy
|
IE911965A1
(en)
|
1990-06-11 |
1991-12-18 |
Iaf Biochem Internat |
Heterocyclic anthracyclinone and anthracycline analogs
|
EP0547065B1
(en)
|
1990-06-29 |
2001-08-29 |
Large Scale Biology Corporation |
Melanin production by transformed microorganisms
|
MY106399A
(en)
|
1990-07-24 |
1995-05-30 |
Pfizer |
Cephalosporins and homologeus, preparation and pharmaceutical composition
|
US5192880A
(en)
|
1990-11-13 |
1993-03-09 |
Nec Corporation |
High-speed emitter coupled logic circuit with large current driving capability
|
KR100211417B1
(ko)
|
1990-11-30 |
1999-10-01 |
유충식 |
L-탈로피라노시드 유도체 및 그의 제조방법
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
NZ241606A
(en)
|
1991-02-28 |
1994-08-26 |
Iaf Biochem Int |
Heteroanthracycline antitumor analogs, preparation and pharmaceutical compositions thereof; intermediates therefor
|
JP3025056B2
(ja)
|
1991-03-12 |
2000-03-27 |
財団法人微生物化学研究会 |
2,6−ジデオキシ−2−フルオロ−l−タロピラノース誘導体の製造法
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
JPH04290891A
(ja)
|
1991-03-19 |
1992-10-15 |
Yasumitsu Tamura |
新規なアンスラサイクリン系化合物
|
DE4111971C1
(zh)
|
1991-04-12 |
1992-03-12 |
Wolf-Dieter Dr. 7803 Gundelfingen De Fessner |
|
US5552534A
(en)
|
1991-08-22 |
1996-09-03 |
The Trustees Of The University Of Pennsylvania |
Non-Peptide peptidomimetics
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
AU675209B2
(en)
|
1991-10-15 |
1997-01-30 |
Scripps Research Institute, The |
Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
WO1993010260A1
(en)
|
1991-11-21 |
1993-05-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
EP0625200B1
(en)
|
1992-02-06 |
2005-05-11 |
Chiron Corporation |
Biosynthetic binding protein for cancer marker
|
US5278311A
(en)
|
1992-06-05 |
1994-01-11 |
E. R. Squibb & Sons, Inc. |
Nonionic radiographic contrast agents
|
US5736523A
(en)
|
1992-11-09 |
1998-04-07 |
Biochem Pharma Inc. |
Antineoplastic heteronapthoquinones
|
DK76193D0
(da)
|
1993-06-25 |
1993-06-25 |
Astra Ab |
Kulhydratderivater
|
US5670315A
(en)
|
1993-09-13 |
1997-09-23 |
Canon Kabushiki Kaisha |
Nucleic acid determination employing pyryilium dye
|
GB9418260D0
(en)
|
1994-09-09 |
1994-10-26 |
Erba Carlo Spa |
Anthracycline derivatives
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
JPH08286368A
(ja)
|
1995-04-14 |
1996-11-01 |
Toyo Ink Mfg Co Ltd |
着色画像形成材料およびそれを用いた着色画像形成媒体と着色画像形成方法
|
US6245347B1
(en)
|
1995-07-28 |
2001-06-12 |
Zars, Inc. |
Methods and apparatus for improved administration of pharmaceutically active compounds
|
CA2184956A1
(en)
|
1995-09-08 |
1997-03-09 |
Tomio Takeuchi |
Fluorine-containing anthracycline derivatives having hydroxyl group(s) mono- or di-o-aminoalkanoylated in the sugar moiety thereof
|
DE19541260A1
(de)
|
1995-11-06 |
1997-05-07 |
Lohmann Therapie Syst Lts |
Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
US6512010B1
(en)
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
PL182601B1
(pl)
|
1996-07-17 |
2002-02-28 |
Waldpharm Sp Z Oo |
Sposób otrzymywania antybiotyków antracyklinowych
|
DE19640969A1
(de)
|
1996-10-04 |
1998-04-16 |
Bayer Ag |
20-0-verknüpfte Glycokonjugate von Camptothecin
|
US5770407A
(en)
|
1996-12-10 |
1998-06-23 |
The Scripps Research Institute |
Process for preparing nucleotide inhibitors of glycosyltransferases
|
FR2764304B1
(fr)
|
1997-06-06 |
1999-07-16 |
Rhone Poulenc Rorer Sa |
Nouvelle classe d'agents transfectants cationiques des acides nucleiques
|
JPH1135593A
(ja)
|
1997-07-18 |
1999-02-09 |
Daikin Ind Ltd |
2−フルオロフコシル−n−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法
|
US6248864B1
(en)
|
1997-12-31 |
2001-06-19 |
Adherex Technologies, Inc. |
Compounds and methods and modulating tissue permeability
|
DK2180007T4
(da)
|
1998-04-20 |
2017-11-27 |
Roche Glycart Ag |
Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
|
US6312717B1
(en)
|
1998-07-07 |
2001-11-06 |
Bristol-Myers Squibb Company |
Method for treatment of anxiety and depression
|
SE9802864D0
(sv)
|
1998-08-27 |
1998-08-27 |
Pharmacia & Upjohn Ab |
Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
|
DE60045319D1
(de)
|
1999-02-05 |
2011-01-13 |
Samsung Electronics Co Ltd |
Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
US6544548B1
(en)
|
1999-09-13 |
2003-04-08 |
Keraplast Technologies, Ltd. |
Keratin-based powders and hydrogel for pharmaceutical applications
|
US20080050809A1
(en)
|
1999-09-28 |
2008-02-28 |
Alejandro Abuin |
Novel human kinases and polynucleotides encoding the same
|
US20040219521A1
(en)
|
2000-01-21 |
2004-11-04 |
Tang Y. Tom |
Novel nucleic acids and polypeptides
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
US6670330B1
(en)
|
2000-05-01 |
2003-12-30 |
Theodore J. Lampidis |
Cancer chemotherapy with 2-deoxy-D-glucose
|
US6696081B2
(en)
|
2000-06-09 |
2004-02-24 |
Duke University |
Carbohydrate based lipid compositions and supramolecular structures comprising same
|
AU2001281886A1
(en)
|
2000-06-26 |
2002-01-08 |
Basf Aktiengesellschaft |
Phosphacyclohexanes and the use thereof in the hydroformylation of olefins
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
MXPA04001072A
(es)
|
2001-08-03 |
2005-02-17 |
Glycart Biotechnology Ag |
Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
|
AU2002366951A1
(en)
|
2001-12-10 |
2003-07-09 |
Nuvelo,Inc. |
Novel nucleic acids and polypeptides
|
WO2003068943A2
(en)
|
2002-02-13 |
2003-08-21 |
Incyte Corporation |
Secreted proteins
|
EP2388265A1
(en)
|
2002-02-22 |
2011-11-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US7193069B2
(en)
|
2002-03-22 |
2007-03-20 |
Research Association For Biotechnology |
Full-length cDNA
|
AUPS247502A0
(en)
|
2002-05-22 |
2002-06-13 |
Griffith University |
An antimicrobial agent
|
DE60335552D1
(de)
|
2002-09-11 |
2011-02-10 |
Genentech Inc |
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
|
US20060199181A1
(en)
|
2002-09-11 |
2006-09-07 |
Genentch, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2004032845A2
(en)
|
2002-10-07 |
2004-04-22 |
Encore Pharmaceuticals, Inc. |
R-nsaid esters and their use
|
ES2457538T3
(es)
|
2003-02-20 |
2014-04-28 |
Seattle Genetics, Inc. |
Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
|
WO2004091499A2
(en)
|
2003-04-09 |
2004-10-28 |
Neose Technologies, Inc. |
Intracellular formation of peptide conjugates
|
WO2005000860A2
(en)
|
2003-06-03 |
2005-01-06 |
The Regents Of The University Of California |
Compositions and methods for treatment of disease with acetylated disaccharides
|
FR2858235B1
(fr)
|
2003-07-31 |
2006-02-17 |
Lab Francais Du Fractionnement |
Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
|
WO2005049562A2
(en)
|
2003-11-17 |
2005-06-02 |
Aromagen Corporation |
Novel cyclic oxygenated compounds having cooling, fragrance, and flavor properties, and uses thereof
|
MXPA06007194A
(es)
|
2003-12-23 |
2007-01-19 |
Progen Ind Ltd |
Imitaciones de glicosaminoglican (gag).
|
PL369253A1
(pl)
|
2004-07-23 |
2006-02-06 |
Zakład Badawczo-Produkcyjny SYNTEX Sp.z o.o. |
Sposób otrzymywania złożonych 2-deoksy-2-jodopiranozydów o wysokiej czystości, szczególnie Annamycyny o czystości farmaceutycznej
|
BRPI0513959A
(pt)
|
2004-07-30 |
2008-05-20 |
Rinat Neuroscience Corp |
anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
|
WO2006040558A1
(en)
|
2004-10-15 |
2006-04-20 |
Astrazeneca Ab |
Substituted adenines and the use thereof
|
CA2587766A1
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
EP3683230A1
(en)
|
2005-05-12 |
2020-07-22 |
ZymoGenetics, Inc. |
Compositions and methods for modulating immune responses
|
EP1885399B1
(en)
|
2005-05-26 |
2010-10-20 |
Seattle Genetics, Inc. |
Humanized anti-cd40 antibodies and their methods of use
|
CA2634146A1
(en)
|
2005-12-19 |
2007-06-28 |
Genizon Biosciences Inc. |
Genemap of the human genes associated with crohn's disease
|
US8242167B2
(en)
|
2006-02-24 |
2012-08-14 |
University Of Miami |
Mannose derivatives for killing tumor cells
|
EP1986660A4
(en)
|
2006-02-24 |
2009-08-26 |
Univ Texas |
HEXOSE-BASED COMPOUNDS FOR TREATING CANCER
|
US20100075377A1
(en)
|
2006-04-13 |
2010-03-25 |
West James W |
Tetramerizing polypeptides and methods of use
|
WO2007124283A2
(en)
|
2006-04-13 |
2007-11-01 |
Zymogenetics, Inc. |
Tetramerizing polypeptides and methods of use
|
US9149489B2
(en)
|
2006-04-27 |
2015-10-06 |
Board Of Regents, University Of Texas System |
Inhibitors of glycolysis useful in the treatment of brain tumors
|
WO2008021290A2
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
DE102006053635B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE102006053637B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
WO2008131024A1
(en)
|
2007-04-17 |
2008-10-30 |
Board Of Regents, The University Of Texas System |
Iodo-hexose compounds useful to treat cancer
|
GB0714514D0
(en)
*
|
2007-07-26 |
2007-09-05 |
Univ City |
Computer system
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP3753947A1
(en)
|
2007-09-14 |
2020-12-23 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
CA2697992C
(en)
|
2007-10-04 |
2017-08-22 |
Zymogenetics, Inc. |
B7 family member zb7h6 and related compositions and methods
|
US8293720B2
(en)
|
2007-12-20 |
2012-10-23 |
Dogwood Pharmaceuticals, Inc. |
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
|
CN101998963B
(zh)
|
2008-02-12 |
2014-09-24 |
陶氏益农公司 |
杀虫组合物
|
JP5260093B2
(ja)
|
2008-03-10 |
2013-08-14 |
クラレノリタケデンタル株式会社 |
重合性単量体、重合性組成物及び歯科用材料
|
MX2010010314A
(es)
|
2008-03-21 |
2011-04-12 |
Gen Hospital Corp |
Compuestos y composiciones para la deteccion y el tratamiento de la enfermedad de alzheimer y trastornos relacionados.
|
CN101555262A
(zh)
|
2008-04-08 |
2009-10-14 |
中国科学院生态环境研究中心 |
六水合三氯化铁(FeCl3·6H2O)选择性脱除糖类化合物异头碳酰基的方法
|
KR101855381B1
(ko)
|
2008-04-09 |
2018-05-09 |
제넨테크, 인크. |
면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
|
CN102076865B
(zh)
|
2008-05-02 |
2016-03-16 |
西雅图基因公司 |
用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
|
WO2009143515A2
(en)
|
2008-05-23 |
2009-11-26 |
University Of Miami |
Treatment using continuous low dose application of sugar analogs
|
CN102388058B
(zh)
|
2009-02-11 |
2014-10-01 |
陶氏益农公司 |
杀虫组合物
|
WO2010105298A1
(en)
|
2009-03-18 |
2010-09-23 |
Simon Barry |
Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t (treg) cells and uses thereof
|
US20120100609A1
(en)
|
2009-03-27 |
2012-04-26 |
Crawford Brett E |
N-linked glycan biosynthesis modulators
|
WO2010122460A1
(en)
|
2009-04-20 |
2010-10-28 |
Pfizer Inc. |
Control of protein glycosylation and compositions and methods relating thereto
|
WO2011019419A1
(en)
|
2009-08-11 |
2011-02-17 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Carbohydrate-mediated tumor targeting
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
US20150259371A1
(en)
|
2010-05-06 |
2015-09-17 |
Simon Fraser University |
Methods and compounds for inhibiting glycosyltransferases
|
CA2802017A1
(en)
|
2010-06-09 |
2011-12-15 |
Zymogenetics, Inc. |
Dimeric vstm3 fusion proteins and related compositions and methods
|
MX360336B
(es)
|
2010-07-16 |
2018-10-30 |
Adimab Llc Star |
Colecciones de anticuerpos.
|
JP5918235B2
(ja)
|
2010-08-05 |
2016-05-18 |
シアトル ジェネティクス,インコーポレーテッド |
フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
|
WO2012021408A1
(en)
|
2010-08-12 |
2012-02-16 |
Novozymes, Inc. |
Compositions comprising a polypeptide having cellulolytic enhancing activity and a dioxy compound and uses thereof
|
TWI410431B
(zh)
|
2010-12-22 |
2013-10-01 |
Ind Tech Res Inst |
齊敦果酸衍生物在製備預防或治療c型肝炎之藥物的用途
|
US8923278B2
(en)
|
2011-01-10 |
2014-12-30 |
Vtech Telecommunications Limited |
Peer-to-peer, internet protocol telephone system with system-wide configuration data
|
EP2663314A2
(en)
|
2011-01-11 |
2013-11-20 |
The University of Texas M.D. Anderson Cancer |
Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
|
US9493452B2
(en)
|
2011-03-24 |
2016-11-15 |
Southern Methodist University |
Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
|
WO2012163489A1
(en)
|
2011-05-31 |
2012-12-06 |
Merck Patent Gmbh |
Compounds containing hydrido-tricyano-borate anions
|
JP5980918B2
(ja)
|
2011-07-15 |
2016-08-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
アルキル−シアノ−ボレートまたはアルキル−シアノ−フルオロボレートアニオンを含む化合物
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
JP6170999B2
(ja)
|
2012-03-13 |
2017-07-26 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
アデノウイルスおよび化学二量体を用いる選択細胞の標的化
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
AU2013266069B2
(en)
|
2012-05-25 |
2018-03-15 |
Sloan Kettering Institute For Cancer Research |
Methods for treating GI syndrome and graft versus host disease
|
EP2858673A4
(en)
|
2012-06-06 |
2016-06-22 |
Oncomed Pharm Inc |
BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF
|
PT2925350T
(pt)
|
2012-12-03 |
2019-03-25 |
Bristol Myers Squibb Co |
Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
|
KR20150090919A
(ko)
|
2012-12-04 |
2015-08-06 |
온코메드 파마슈티칼스, 인크. |
결합제를 사용한 면역요법
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
EP3021869B1
(en)
|
2013-07-16 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
US20150132744A1
(en)
|
2013-11-13 |
2015-05-14 |
Oregon Health And Science University |
Methods of detecting cells latently infected with hiv
|
WO2015097536A2
(en)
*
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
WO2015143343A2
(en)
|
2014-03-21 |
2015-09-24 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
PE20170140A1
(es)
|
2014-07-16 |
2017-03-30 |
Genentech Inc |
Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
|
MA40475A
(fr)
|
2014-08-19 |
2017-06-28 |
Fayadat Dilman Laurence |
Anticorps anti-tigit
|
EP3212230B1
(en)
|
2014-10-29 |
2021-01-20 |
Seagen Inc. |
Dosage and administration of non-fucosylated anti-cd40 antibodies
|
WO2016073704A1
(en)
|
2014-11-06 |
2016-05-12 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
WO2016073879A2
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Transforming growth factor-related antibodies and uses thereof
|
SG11201703376QA
(en)
|
2014-11-06 |
2017-05-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
EP3220927B1
(en)
|
2014-11-20 |
2022-01-05 |
Promega Corporation |
Systems and methods for assessing modulators of immune checkpoints
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
DK3237446T3
(en)
|
2014-12-22 |
2021-07-26 |
Pd 1 Acquisition Group Llc |
Anti-PD-1-antistoffer
|
AU2015369683B2
(en)
|
2014-12-23 |
2020-12-10 |
Bristol-Myers Squibb Company |
Antibodies to TIGIT
|
AU2016209337A1
(en)
|
2015-01-20 |
2017-07-13 |
Immunexcite, Inc. |
Compositions and methods for cancer immunotherapy
|
DK3295951T3
(da)
|
2015-02-19 |
2020-07-20 |
Compugen Ltd |
Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
|
US10550173B2
(en)
|
2015-02-19 |
2020-02-04 |
Compugen, Ltd. |
PVRIG polypeptides and methods of treatment
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
PT3283508T
(pt)
|
2015-04-17 |
2021-06-21 |
Alpine Immune Sciences Inc |
Proteínas imuno modulatórias com afinidades afináveis
|
US11022615B2
(en)
|
2015-05-04 |
2021-06-01 |
University Of Florida Research Foundation, Inc. |
Regulatory T-cells, method for their isolation and uses
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Tigit結合劑和彼之用途
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
AU2016270996A1
(en)
|
2015-06-03 |
2017-11-23 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce conversion of regulatory T cells into effector T cells for cancer immunotherapy
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
EP3334757A4
(en)
*
|
2015-08-14 |
2019-04-03 |
Merck Sharp & Dohme Corp. |
ANTI-TIGIT ANTIBODIES
|
WO2017040660A1
(en)
|
2015-08-31 |
2017-03-09 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
WO2017040666A2
(en)
|
2015-08-31 |
2017-03-09 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
CN108137691B
(zh)
|
2015-09-02 |
2021-10-19 |
耶路撒冷希伯来大学伊萨姆研究发展有限公司 |
特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
|
CA2997551A1
(en)
|
2015-09-04 |
2017-03-09 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
WO2017048878A1
(en)
|
2015-09-14 |
2017-03-23 |
Alpine Immune Sciences, Inc. |
Tunable variant immunoglobulin superfamily domains and engineered cell therapy
|
WO2017048824A1
(en)
|
2015-09-14 |
2017-03-23 |
Compass Therapeutics Llc |
COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-β
|
AU2016325610B2
(en)
*
|
2015-09-25 |
2019-10-10 |
Genentech, Inc. |
Anti-TIGIT antibodies and methods of use
|
KR20180051651A
(ko)
|
2015-10-01 |
2018-05-16 |
히트 바이오로직스, 인코퍼레이티드 |
비상동성 키메라 단백질로서의 i형 및 ii형 세포외 도메인을 인접시키기 위한 조성물 및 방법
|
PL3356413T3
(pl)
|
2015-10-01 |
2022-04-19 |
Potenza Therapeutics, Inc. |
Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
|
US10894830B2
(en)
|
2015-11-03 |
2021-01-19 |
Janssen Biotech, Inc. |
Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
|
AU2016362993A1
(en)
|
2015-12-04 |
2018-07-12 |
Seagen Inc. |
Cancer treatment using 2-deoxy-2-fluoro-L-fucose in combination with a checkpoint inhibitor
|
US11648268B2
(en)
|
2015-12-09 |
2023-05-16 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of using same
|
IL296874A
(en)
|
2016-03-01 |
2022-11-01 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Antibodies specific for the human poliovirus receptor
|
MY191649A
(en)
|
2016-03-04 |
2022-07-05 |
Jn Biosciences Llc |
Antibodies to tigit
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
CN109715657A
(zh)
|
2016-04-15 |
2019-05-03 |
高山免疫科学股份有限公司 |
Cd80变体免疫调节蛋白及其用途
|
US10882914B2
(en)
|
2016-04-15 |
2021-01-05 |
Alpine Immune Sciences, Inc. |
ICOS ligand variant immunomodulatory proteins and uses thereof
|
US11078247B2
(en)
|
2016-05-04 |
2021-08-03 |
Curevac Ag |
RNA encoding a therapeutic protein
|
WO2017193059A1
(en)
|
2016-05-06 |
2017-11-09 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
JP7358047B2
(ja)
|
2016-05-16 |
2023-10-10 |
チェックマブ エス.アール.エル. |
腫瘍浸潤制御性t細胞において選択的に脱制御されたマーカー
|
CN109475603B
(zh)
|
2016-06-20 |
2023-06-13 |
科马布有限公司 |
抗pd-l1抗体
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
MY194032A
(en)
|
2016-08-17 |
2022-11-09 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
JP2019528699A
(ja)
|
2016-08-30 |
2019-10-17 |
メモリアル スローン ケタリング キャンサー センター |
ウイルスおよびその他の感染を処置するための免疫細胞組成物および使用の方法
|
WO2018041120A1
(en)
|
2016-08-31 |
2018-03-08 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric tigit
|
IL300982B1
(en)
|
2016-09-10 |
2024-04-01 |
Yeda Res & Dev |
Reduction of the level of regulatory T cells or their activity for the treatment of diseases and damages in the central nervous system
|
EP3293271A1
(en)
|
2016-09-12 |
2018-03-14 |
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin |
Marker and target as a diagnostic variable and target for therapy of metastatic cancer
|
US20190225701A1
(en)
|
2016-09-26 |
2019-07-25 |
The Brigham And Women's Hospital, Inc. |
Regulators of b cell-mediated immunosuppression
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
MX2019010206A
(es)
|
2017-02-28 |
2019-12-11 |
Seattle Genetics Inc |
Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit).
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|